Collaborations to Enhance Drug Development and Regulatory Science
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you're building tools, processes, or partnerships to accelerate drug development or regulatory decision-making, the FDA wants to fund collaborative solutions.
Report stale or inaccurate summary
What this is
This FDA program funds collaborative projects designed to enhance drug development efficiency and regulatory decision-making. It targets partnerships that combine expertise across industry, academic institutions, and regulatory agencies to tackle bottlenecks in drug approval, data standards, and scientific evaluation methods. The program is ideal for organizations seeking to innovate in pharmaceutical development workflows and regulatory compliance. Limited public details are available; applicants should review the full solicitation for specific technical priorities and award amounts.
Who can apply
Eligibility criteria are not specified in the provided text. Applicants should assume FDA grants typically require tax-exempt 501(c)(3) status, academic institutions, or qualified businesses; consult the full solicitation for definitive requirements, geographic restrictions, and mandatory collaborative structure.
Topics: drug development · regulatory science · fda collaboration · pharmaceutical innovation · drug approval process · regulatory pathway
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.